Arax Advisory Partners’s Kazia Therapeutics KZIA Stock Holding History

Arax Advisory Partners’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23K	Buy	+87	New	+$1.06K	﹤0.01%	4901
2026 Q1	–	Sell	-200	Closed	-$1.38K	–	4096
2025 Q4	$1.38K	Hold	200	–	–	﹤0.01%	3394
2025 Q3	$1.44K	Hold	200	–	–	﹤0.01%	3178
2025 Q2	$1.25K	Hold	200	–	–	﹤0.01%	2712
2025 Q1	$783	Buy	+200	New	+$1.18K	﹤0.01%	2391

Other funds holding KZIA

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arax Advisory Partners's KZIA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Kazia Therapeutics (KZIA) in Q2 2026: 87 shares worth $1.23K. The stake represents ﹤0.01% of the portfolio and ranks #4901 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in KZIA as recently as Q4 2025.

Arax Advisory Partners first reported a position in KZIA in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.44K in Q3 2025. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

Arax Advisory Partners held 87 shares of Kazia Therapeutics worth $1.23K as of Q2 2026.
Kazia Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Kazia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4901 holding.
Arax Advisory Partners first reported a position in Kazia Therapeutics in Q1 2025 and has held it in 5 quarters since.
Arax Advisory Partners's Kazia Therapeutics position peaked at $1.44K in Q3 2025.
35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.